What’s Hot and What’s Not in Oncology Licensing in 2020?
What’s Hot and What’s Not in Oncology Licensing in 2020?
Cancer is the biggest therapeutic area for licensing deals. But there are almost 3,000 drugs in Phase 1 through Phase 3, so competition for licensing deals and for market position is huge. Checkpoint inhibitors have benefits in most tumors and have made combination trials an industry standard. But everything in immuno-oncology has become so crowded that differentiation is key. So what are the areas everyone is seeking?
About 6% of Phase 1 trials in oncology are targets with no drugs in higher phases. What are these new targets? What is promising for tough tumors like pancreatic and microsatellite stable colorectal? What is promising in addressing resistance? Are there new theories of cancer? Are bispecifics becoming plug and play? Will they displace CART? What is coming around the corner? Is there still room for a new therapeutic in anti-angiogenesis, supportive care? Is pricing pressure going to change what is an acceptable oncology asset for a deal? What does it take to get a cancer licensing deal done?
In this whitepaper, Linda Pullan, PhD of
Pullan Consulting
and our panel of experts provide insights in oncology and immuno-oncology to answer these questions, as well as questions from the audience.
EXPERT PANEL

Linda Pullan, PhD
Founder, Pullan Consulting
Linda
and her team at Pullan Consulting offer biotech and pharmaceutical
companies consulting in all aspects of partnering. Linda has a PhD in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals. Learn More

Jeffrey M. Bockman, PhD
EVP, Oncology Practice Head, Cello Health BioConsultin
Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting (Previously Defined Health). He received a BA from the University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn More

Peter Sandor
SVP Oncology, Astellas Pharma
Peter serves as SVP Primary Focus Lead, responsible for strategic direction, execution and leadership of research, development, manufacturing and commercial of Immuno-Oncology at Astellas globally. Learn More

Asthika Goonewardene
Managing Director, Senior Biotech Analyst at SunTrust Robinson Humphrey
Asthika Goonewardene is a Managing Director at SunTrust Robinson Humphrey (STRH) covering biotechnology companies with a focus on cell therapy, immuno-oncology, and antibody technology. Prior to joining the STRH Biotech team in 2019, Asthika was a senior analyst with Bloomberg Intelligence, leading coverage of the global biotech sector. Before joining Bloomberg in 2011, Asthika worked as a senior management consultant at Datamonitor. He started his career as an analyst at OSI Pharmaceuticals in 2005, and first joined the sell-side in 2007, with the biotech team at Piper Jaffray in London. Asthika holds a BS in Biotechnology and an MBA in Technology Management from Rochester Institute of Technology. Learn More
